Clinical Trials

86 enrolled

Prostatic Neoplasms

NCT05176483 2026-05-27

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT05562830 2026-05-27

MK-3475-04A

48 enrolled

Carcinoma, Transitional Cell

NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

30 enrolled

Prostatic Neoplasms

NCT05710848 2026-05-27

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

75 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05939414 2026-05-27

PSMA-DC

450 enrolled

Oligometastatic Prostate Cancer (OMPC)

NCT06136650 2026-05-27

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

520 enrolled

Prostatic Neoplasms

NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06780670 2026-05-27

PSMAcTION

Phase 2/3 Recruiting

443 enrolled

Prostatic Neoplasms

NCT06904625 2026-05-27

CAPT CTC

54 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT07252726 2026-05-27

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Phase 4 Recruiting

50 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07607990 2026-05-27

Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP

130 enrolled

Prostatic Neoplasms

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05987241 2026-05-26

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

992 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06147037 2026-05-26

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

GastrointestinalGenitourinaryHead & NeckThoracic

70 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Stomach Neoplasms, Colorectal Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06492122 2026-05-26

ProTACT

50 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06508567 2026-05-26

SHAPE-PSMA

20 enrolled

Prostatic Neoplasms

NCT06574880 2026-05-26

STARLiT

45 enrolled

Prostatic Neoplasms

NCT07049926 2026-05-26

MK-3475-03C

140 enrolled

Carcinoma, Renal Cell

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT07293351 2026-05-26

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

254 enrolled

Carcinoma, Renal Cell

NCT07405164 2026-05-26

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07475403 2026-05-26

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

53 enrolled

Urinary Bladder Neoplasms

NCT07489495 2026-05-26

LITESPARK-034

758 enrolled

Carcinoma, Renal Cell

NCT07524426 2026-05-26

LORUP

248 enrolled

Urinary Bladder Neoplasms

NCT05225428 2026-05-22

VERDI

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcoma

1,020 enrolled

Breast Neoplasms, Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05287945 2026-05-22

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

75 enrolled

Carcinoma, Renal Cell, Kidney Failure, Chronic, Kidney Neoplasms, Neoplasm Metastasis

NCT05616650 2026-05-22

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

42 enrolled

Prostatic Neoplasms

NCT06041503 2026-05-22

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

68 enrolled

Adenocarcinoma of the Bladder

NCT06465069 2026-05-22

NEXUS-01

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06510374 2026-05-22

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06545955 2026-05-22

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT06842498 2026-05-22

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

75 enrolled

Prostatic Neoplasms

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06986083 2026-05-22

A Study of Changes to Prostate Procedures

800 enrolled

Prostatic Neoplasms

NCT07023432 2026-05-22

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

78 enrolled

Carcinoma, Renal Cell

NCT07028853 2026-05-22

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT07114601 2026-05-22

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07140315 2026-05-22

DK222 Study at Hopkins

6 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07172958 2026-05-22

SABRE

18 enrolled

CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing

NCT07213674 2026-05-22

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07218380 2026-05-22

FORAGER-2

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07218718 2026-05-22

Oral Cryotherapy to Decrease Taste Changes in Prostate Cancer Patients Receiving Taxane Chemotherapy

60 enrolled

Prostatic Neoplasms

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

224 enrolled